Journal: Oncology reports

Article Title: MicroRNA-124 inhibits cell proliferation and migration by regulating SNAI2 in breast cancer.

doi: 10.3892/or.2016.5163

Figure Lengend Snippet: Figure 3. Snail family zinc finger 2 (SNAI2) is a target of miR-21 in breast cancer. (A) Sequence alignment of human miR-124 with the 3'-untranslated region (3'‑UTR) of SNAI2. The seed sequence of miR-124 matches the 3'-UTR of SNAI2. (B) Correlation between the ratio of miR-124 expression in the breast cancer tissues compared to adjacent normal tissues and SNAI2. The r-values were calculated by Spearman correlation analysis. (C) The expression level of SNAI2 was significantly increased in breast cancer cell lines compared to MCF-10A cells. The graph displays the mean of 2-∆∆Ct value ± SEM; ***P<0.001. (D) Western blotting assay of MCF-7 cells transfected with miR-124. (E) Effect of miR-124 on SNAI2 expression as determined by a luciferase reporter assay. The data were normalized by determining the ratio of firefly and Renilla luciferase activities measured at 24-h post-transfection. The results shown represent the mean ± SEM of triplicate experiments. ***P<0.001; n.s., not significant.

Article Snippet: Short hairpin RNA (shRNA) constructs against SNAI2 were from Origene Co. (GenePharma).

Techniques: Sequencing, Expressing, Western Blot, Transfection, Luciferase, Reporter Assay

Journal: Oncology reports

Article Title: MicroRNA-124 inhibits cell proliferation and migration by regulating SNAI2 in breast cancer.

doi: 10.3892/or.2016.5163

Figure Lengend Snippet: Figure 4. Inhibition of snail family zinc finger 2 (SNAI2) reduces tumorigenic activity in breast cancer cells. (A) Western blotting validated the downregulation of SNAI2 after short hairpin RNA (shRNA) knockdown in MCF-7 cells. (B-F) SNAI2 knockdown reduces the proliferation capacity (B), colony formation capacity (C), migration capacity (D and E) and invasion capacity (F) of MCF-7 cells. Bar graphs display mean ± SEM of triplicate experiments. **P<0.01, ***P<0.001.

Article Snippet: Short hairpin RNA (shRNA) constructs against SNAI2 were from Origene Co. (GenePharma).

Techniques: Inhibition, Activity Assay, Western Blot, shRNA, Knockdown, Migration

Journal: Scientific reports

Article Title: PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.

doi: 10.1038/s41598-022-16623-3

Figure Lengend Snippet: Figure 2. Cell line-dependent reversibility of acquired Talazoparib resistance. (a) Immunoblot showing PAR level of PSN1 parental cells, TalaR cells maintained in media with Talazoparib (TalaR-M) and TalaR cells cultured in drug-free media for 4 weeks (TalaR-DF). (b) Talazoparib IC50 chart showing reversibility of acquired resistance in PSN1 cells over 4 weeks after drug withdrawal. (c–f) Clonogenic assay showing Talazoparib sensitivity of parental and acquired resistant cells in PSN1, PANC1, SW1990 and HCC1806 cells which were maintained in drug media (Tala-M) and in drug free media for 4 weeks (Tala-DF). (g, h) Volcano plots showing differentially expressed genes between TalaR-M and TalaR-DF in PSN1 and HCC1806 cells. (i, j) UMAP representations of HCC1806 parental and resistant subpools, colored by cell line (i) or cluster identity (j). (k, l) Violin plots of SNAI2 (k) and TWIST1 (l) gene expression profile across subpopulation clusters shown in (j).

Article Snippet: SNAI2 cDNA expressing plasmid was purchased from Origene (RC202365) and transfected into cells by using Fugene HD transfection reagent (Promega).

Techniques: Western Blot, Cell Culture, Clonogenic Assay, Gene Expression

Journal: Scientific reports

Article Title: PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.

doi: 10.1038/s41598-022-16623-3

Figure Lengend Snippet: Figure 5. CHD1L depletion re-sensitizes cells with acquired resistance to Talazoparib. (a) Clonogenic assay showing growth of PSN1 TalaR-M cells with CHD1L stable knockdown. (b) Immunoblot showing expression level of CHD1L and SNAI2 in CHD1L stable knockdown cells as in (a). (c) IncuCyte curves showing the growth PSN1 TalaR-M with inducible CHD1L knockdown with and without doxycycline induction. (d) qPCR showing mRNA level of CHD1L and SNAI2 in PSN1 TalaR-M with inducible CHD1L knockdown with and without doxycycline induction as in (c). (e) IncuCyte curves showing the growth of PSN1 parental and TalaR-M with CHD1L knockout. (f) IncuCyte curves showing the growth of HCC1806 parental and TalaR-M with CHD1L knockout. (g, h) Immunoblot and qPCR showing CHD1L and SNAI2 level in HCC1806 parental and TalaR-M with CHD1L knockout as in (f).

Article Snippet: SNAI2 cDNA expressing plasmid was purchased from Origene (RC202365) and transfected into cells by using Fugene HD transfection reagent (Promega).

Techniques: Clonogenic Assay, Knockdown, Western Blot, Expressing, Knock-Out